Association Between Testosterone Replacement Therapy and Prostatic Disorders in Elderly Hypogonadal Men
Abstract
CONTEXT: Concerns about potential prostate-related complications associated with testosterone replacement therapy (TRT) often lead hypogonadal men to remain untreated.
METHODS: This large-scale retrospective cohort study aimed to address these concerns by analyzing Medicare enrollment and claims data (Parts A/B/C/D) from 2007 to 2020 for men aged ≥65 with diagnosed primary or secondary hypogonadism. Cox regression analysis and 1:1 propensity score matching, both stratified by age group, were employed to evaluate the association between prostate outcomes and TRT use. TRT use was further categorized by treatment duration, administration route, and aromatase inhibitor (AI) coadministration.
RESULTS: Following propensity score matching, the prostate cancer (PCa) and benign prostatic hyperplasia (BPH) risk analyses included 546 964 and 412 782 hypogonadal men, respectively, with comparable baseline characteristics at the time of hypogonadism diagnosis. TRT use was linked to a significant 16% reduction in the hazard of PCa (HR = 0.84; 95% CI: 0.82-0.86), including reductions observed across long-term (15%), short-term (16%), parenteral (12%), and topical (13%) use. Sensitivity analyses excluding individuals with elevated prostate-specific antigen and family history of PCa similarly demonstrated a 18% reduction in the hazard of PCa among TRT users. Conversely, TRT use exhibited a 13% increase in the hazard of BPH (HR = 1.13; 95% CI: 1.11-1.14), with a larger increase for parenteral…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 412 participants or records.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.